Opendata, web and dolomites

CANDY SIGNED

Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CANDY project word cloud

Explore the words cloud of the CANDY project. It provides you a very rough idea of what is the project "CANDY" about.

biomarkers    cancer    intellectual    guide    translational    autoimmune    risk    hope    lifespan    autism    time    caused    15    transform    neurotransmission    stroke    personalized    id    immune    glutamate    hyperactivity    people    subgroups    data    leverage    clinically    illnesses    medicine    understand    first       converge    excitation    batteries    treatments    lack    mortality    stratification    monitoring    team    academics    acting    rare    neurodevelopmental    multidisciplinary    multimorbidity    disorder    heterogeneous    shared    bases    variants    asd    candy    patient    landscape    spend    underpinning    co    prevention    mental    strategies    population    dysregulation    disorders    genetic    adhd    instance    world    epilepsy    deficit    shows    life    individuals    gastrointestinal    gaba    stages    sensitive    imbalance    spectrum    played    economic    hence    smes    dementia    plasticity    inhibition    activation    innovation    disease    synaptic    morbidity    diagnosis    tools    combination    treatment    disability    ndds    valorization    periods    mechanisms    somatic    final   

Project "CANDY" data sheet

The following table provides information about the project.

Coordinator
STICHTING KATHOLIEKE UNIVERSITEIT 

Organization address
address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ
website: www.radboudumc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 6˙000˙000 €
 EC max contribution 6˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) coordinator 1˙615˙000.00
2    KING'S COLLEGE LONDON UK (LONDON) participant 825˙000.00
3    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 500˙000.00
4    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 425˙000.00
5    ARTTIC FR (PARIS) participant 350˙000.00
6    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 350˙000.00
7    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 300˙000.00
8    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 300˙000.00
9    UNIVERSITEIT GENT BE (GENT) participant 300˙000.00
10    RIJKSUNIVERSITEIT GRONINGEN NL (GRONINGEN) participant 250˙000.00
11    UNIVERSITAT BASEL CH (BASEL) participant 250˙000.00
12    NOLDUS INFORMATION TECHNOLOGY BV NL (WAGENINGEN) participant 200˙000.00
13    UNIVERSITAET ULM DE (ULM) participant 150˙000.00
14    BIRKBECK COLLEGE - UNIVERSITY OF LONDON UK (LONDON) participant 125˙000.00
15    ADD INFORMATION SERVICES UK (LONDON) participant 30˙000.00
16    AUTISME-EUROPE AISBL BE (BRUXELLES) participant 30˙000.00

Map

 Project objective

Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and intellectual disability (ID) are clinically heterogeneous, often co-occur, affect ~15% of the EU population; and are associated with somatic illnesses (e.g. epilepsy, autoimmune and gastrointestinal disease) that lead to a significant increase in morbidity and mortality. For instance in ASD the combination of ID and epilepsy is associated with a reduction in lifespan of ~ 20 years; and an economic cost that is greater than cancer, stroke, or dementia. Yet, the research spend on NDDs is less than 1% of those disorders. Hence, we lack effective new treatments for NDDs and do not understand why they co-occur. There is hope, however. Recent evidence shows that rare genetic variants increasing risk for NDDs are shared, converge on final common pathways (e.g. synaptic plasticity, glutamate and GABA neurotransmission, and excitation/inhibition imbalance), and a key role is likely played by immune dysregulation. CANDY’s innovation is to test, for the first time, if NDDs, and their common mental and somatic multimorbidity, are caused by a combination(s) of common and rare genetic variants and immune activation acting at different ‘sensitive periods’. Our multidisciplinary team of world leading academics, patient organizations and SMEs will cost-effectively leverage existing EU-funded studies to 1) identify novel mechanisms underpinning NDDs and their multimorbidity, 2) develop new strategies for prevention and treatment, 3) deliver novel biomarkers to guide early diagnosis, stratification and/or treatment monitoring, and 4) provide open-access data bases, translational test batteries, and tools and targets for valorization. Together we will transform the landscape for people with NDDs and make possible personalized medicine approaches that target particular mechanisms, in specific subgroups of individuals and at different life stages.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CANDY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CANDY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

ARREST-TB (2019)

Accurate, Rapid, Robust and Economical diagnostic technoliogieS for Tuberculosis

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More  

ESPACE (2020)

Human Cell Atlas of the Pancreas

Read More